Michael Sarcone
Stock Analyst at Jefferies
(0.18)
# 3,314
Out of 4,433 analysts
4
Total ratings
33.33%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
4 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Upgrades: Buy | $84 → $125 | $109.79 | +13.85% | 1 | May 6, 2024 | |
| PROF Profound Medical | Downgrades: Equal-Weight | $5.5 → $10 | $8.29 | +20.63% | 1 | Mar 21, 2023 | |
| AXGN AxoGen | Assumes: Buy | $15 | $6.04 | +148.34% | 1 | Nov 11, 2022 | |
| EDAP EDAP TMS | Initiates: Buy | $11 | $6.71 | +63.93% | 1 | Nov 1, 2022 |
Glaukos
May 6, 2024
Upgrades: Buy
Price Target: $84 → $125
Current: $109.79
Upside: +13.85%
Profound Medical
Mar 21, 2023
Downgrades: Equal-Weight
Price Target: $5.5 → $10
Current: $8.29
Upside: +20.63%
AxoGen
Nov 11, 2022
Assumes: Buy
Price Target: $15
Current: $6.04
Upside: +148.34%
EDAP TMS
Nov 1, 2022
Initiates: Buy
Price Target: $11
Current: $6.71
Upside: +63.93%